The VENTANA PD-L1 (SP142) Assay:
- FDA approved to assess NSCLC patient treatment benefit from TECENTRIQ® (atezolizumab)
- Informative for the clinician of a patient’s potential overall survival
- Novel scoring algorithm using PD-L1 staining in both TC and IC
- Designed to enhance visual contrast of immune cell staining within the tumor microenvironment
The PD-L1 (SP142) Assay gives you the confidence to guide immunotherapy decisions in NSCLC.
*All randomized patients in a NSCLC phase III study observed benefit from TECENTRIQ (atezolizumab) regardless of PD-L1 status